Cisatracurium

Overview

Cisatracurium is a non-depolarising neuromuscular blocking agent of the benzylisoquinolinium class, available in its salt form, cisatracurium besylate. Cisatracurium has an intermediate duration of action and is one of the most commonly used neuromuscular blocking agents in intensive care.. Cisatracurium acts on cholinergic receptors, blocking neuromuscular transmission. This action is antagonized by acetylcholinesterase inhibitors such as neostigmine. Cisatracurium is an R-cis-R-cis isomer of atracurium and has approximately 3 times its neuromuscular blocking potency. Compared to atracurium, cisatracurium produces a lower degree of histamine release.

Indication

Cisatracurium is indicated as an adjunct to general anesthesia to facilitate tracheal intubation in adults and pediatric patients 1 month to 12 years of age. Cisatracurium is also indicated to provide skeletal muscle relaxation during surgery in adults and pediatric patients 2 to 12 years of age as a bolus or infusion maintenance and for mechanical ventilation in the ICU in adults.

Associated Conditions

No associated conditions information available.

Clinical Trials

Title	Posted	Study ID	Phase	Status	Sponsor
Effect of Different Depths of Neuromuscular Blockade on Respiratory Mechanics in Patients With Moderate-severe Acute Respiratory Distress Syndrome	2024/07/23	NCT06514209	Not Applicable	Recruiting	Southeast University, China
Effect of Addition of Cisatracurium to Lidocaine VS Plain Lidocaine	2024/01/19	NCT06214169	Not Applicable	Completed	Watim Medical & Dental College
The Efficacy of P0.1-guided Sedation Protocol in Critically Ill Patients Receiving Invasive Mechanical Ventilation: A Randomized Controlled Trial	2024/01/12	NCT06203405	Not Applicable	Recruiting	Siriraj Hospital
Rocuronium vs Cis-atracurium: Do Rocuronium Still 'ROCKS' In Coronary Artery Bypass Grafting	2023/10/26	NCT06102915	N/A	Completed	Institut Jantung Negara
Median Effective Dose of Cisatracurium for the Prevention of Fasciculation Caused by the Injection of Succinylcholine	2023/03/09	NCT05760976	Not Applicable	Recruiting	Yangzhou University
Effect of Rematazolam Besylate, Propofol, and Sevoflurane Perioperative Sedation on Incidence of Emergence Agitation and Hemodynamics in Patients Undergoing Laparoscopic Abdominal Surgery	2022/11/22	NCT05624424	Phase 4	Not yet recruiting	Second Affiliated Hospital of Nanchang University
Effect of Remimazolam vs Sevoflurane Anesthesia on Incidence of Emergence Agitation and Complications in Children Undergoing Ophthalmic Surgery	2022/09/02	NCT05527314	Not Applicable	Completed	Second Affiliated Hospital of Nanchang University
Muscle Relaxants and Laryngeal Local Anesthetics for Laryngeal Mask Airway Insertion Decreasing Propofol in Elderly	2022/04/04	NCT05310110	Not Applicable	Completed	Chang Gung Memorial Hospital
Efficacy and Safety Profile of Cisatracurium Besylate for IAH	2021/12/29	NCT05172531	Not Applicable	UNKNOWN	Tianjin Nankai Hospital
Continuous Infusion Versus Intermittent Boluses of Cisatracurium in the Early Management of Pediatric ARDS	2021/12/10	NCT05153525	Phase 4	UNKNOWN	Tanta University

FDA Drug Approvals

Approved Product	Manufacturer	NDC Code	Route	Strength	Effective Date
cisatracurium besylate	Zydus Lifesciences Limited	72785-0009	INTRAVENOUS	10 mg in 1 mL	11/5/2022
Cisatracurium Besylate	Meitheal Pharmaceuticals Inc.	71288-712	INTRAVENOUS	10 mg in 5 mL	4/20/2023
Cisatracurium Besylate	Teva Parenteral Medicines, Inc.	0703-2045	INTRAVENOUS	200 mg in 20 mL	11/28/2023
Cisatracurium Besylate	Eugia US LLC	55150-284	INTRAVENOUS	10 mg in 5 mL	4/27/2023
cisatracurium besylate	Sandoz Inc	0781-3150	INTRAVENOUS	2 mg in 1 mL	4/26/2017
Cisatracurium Besylate	Hospira, Inc.	0409-7083	INTRAVENOUS	2 mg in 1 mL	12/5/2022
Cisatracurium Besylate	Meitheal Pharmaceuticals Inc.	71288-714	INTRAVENOUS	20 mg in 10 mL	5/31/2019
Cisatracurium besylate	PIRAMAL CRITICAL CARE INC	66794-246	INTRAVENOUS	200 mg in 20 mL	8/9/2023
Cisatracurium besylate	PIRAMAL CRITICAL CARE INC	66794-245	INTRAVENOUS	10 mg in 5 mL	8/9/2023
Cisatracurium Besylate	Somerset Therapeutics, LLC	70069-161	INTRAVENOUS	2 mg in 1 mL	6/7/2023

EMA Drug Approvals

Approved Product	Authorization Holder	Status	Issued Date
No EMA approvals found for this drug.

HSA Drug Approvals

Approved Product	Manufacturer	Approval Number	Dosage Form	Strength	Approval Date
Nimbex Forte Injection 150 mg/30 ml	GlaxoSmithKline Manufacturing S.p.A.	SIN14310P	INJECTION, SOLUTION	150 mg/30 ml	2/5/2013
Nimbex Injection 2 mg/ml	GlaxoSmithKline Manufacturing S.p.A.	SIN14309P	INJECTION, SOLUTION	2 mg/ml	2/5/2013

NMPA Drug Approvals

Approved Product	Company	Approval Number	Drug Type	Dosage Form	Approval Date
No NMPA approvals found for this drug.

PPB Drug Approvals

Approved Product	Registration No.	Company	Licence No.	Strength	Registration Date
No PPB approvals found for this drug.

TGA Drug Approvals

Approved Product	ARTG ID	Sponsor	Registration Type	Status	Registration Date
CISATRACURIUM AJS cisatracurium (as besilate) 150mg/30mL injection solution in vial	181600	Southern Cross Pharma Pty Ltd	Medicine	A	5/29/2013
CISATRACURIUM AJS cisatracurium (as besilate) 10mg/5mL injection solution in vial	180282	Southern Cross Pharma Pty Ltd	Medicine	A	5/29/2013
GenRx Cisatracurium cisatracurium (as besilate) 20 mg / 10 mL solution for injection ampoule	237308	Arrotex Pharmaceuticals Pty Ltd	Medicine	A	4/12/2016
Cisatracurium APOTEX cisatracurium (as besilate) 20 mg / 10 mL solution for injection ampoule	237306	Arrotex Pharmaceuticals Pty Ltd	Medicine	A	4/12/2016
CISATRACURIUM MYLAN cisatracurium (as besilate) 150 mg/30 mL solution for injection vial	272742	MedTAS Pty Ltd	Medicine	A	1/19/2022
CISATRACURIUM MEDICIANZ cisatracurium (as besilate) 5 mg/2.5 mL injection ampoule	401121	Medsurge Pharma Pty Ltd	Medicine	A	10/11/2023
NIMBEX cisatracurium (as besilate) 5mg/2.5mL injection ampoule	55913	Aspen Pharmacare Australia Pty Ltd	Medicine	A	9/13/1996
CISATRACURIUM ACCORD cisatracurium (as besilate) 150 mg / 30 mL solution for injection vial	222413	Accord Healthcare Pty Ltd	Medicine	A	3/19/2015
Cisatracurium APOTEX cisatracurium (as besilate) 5 mg / 2.5 mL solution for injection ampoule	237312	Arrotex Pharmaceuticals Pty Ltd	Medicine	A	4/12/2016
NIMBEX cisatracurium (as besilate) 50mg/25mL injection ampoule	55933	Aspen Pharmacare Australia Pty Ltd	Medicine	A	9/13/1996

Health Canada Drug Approvals

Approved Product	Company	DIN	Dosage Form	Strength	Market Date
No Health Canada approvals found for this drug.

CIMA AEMPS Drug Approvals

Approved Product	Company	Registration Number	Pharmaceutical Form	Prescription Type	Status
No CIMA AEMPS (Spain) approvals found for this drug.

Philippines FDA Drug Approvals

Approved Product	Company	License Number	Dosage Form	Strength	Approval Date
No Philippines FDA approvals found for this drug.

Saudi SFDA Drug Approvals

Approved Product	Company	License Number	Dosage Form	Strength	Approval Date
No Saudi SFDA approvals found for this drug.

Malaysia NPRA Drug Approvals

Approved Product	Company	Registration Number	Dosage Form	Strength	Approval Date
No Malaysia NPRA approvals found for this drug.

UK EMC Drug Information

Medicine Name	MA Holder	MA Number	Pharmaceutical Form	Active Ingredient	Authorization Date
No UK EMC drug information found for this drug.

AI-Powered Research

Premium Access